We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$7.91B
AUM Growth
-$1.41B
Cap. Flow
-$1B
Cap. Flow %
-12.68%
Top 10 Hldgs %
40.65%
Holding
174
New
35
Increased
19
Reduced
37
Closed
35

Top Buys

Rank Stock Value
1
LABP
Landos Biopharma, Inc. Common Stock
LABP
+$194M
2
BBIO icon
BridgeBio Pharma
BBIO
+$68.7M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$68.4M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$62.1M
5
SWTX
SpringWorks Therapeutics
SWTX
+$52.6M

Top Sells

Rank Stock Value
1
NVAX icon
Novavax
NVAX
+$116M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$100M
3
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$90.4M
4
NVTA
Invitae Corporation
NVTA
+$87.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$87.3M

Sector Composition

Rank Sector Weight
1 Healthcare 80.08%
2 Financials 0.47%
3 Industrials 0.2%
4 Consumer Discretionary 0.02%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRRO icon
76
Korro Bio
KRRO
$147M
$20.1M 0.25%
42,273
-22,920
-35% -$44.5M
FDMT icon
77
4D Molecular Therapeutics
FDMT
$508M
$19.3M 0.24%
444,878
-155,378
-26% -$6.88M
SILK
78
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$17.2M 0.22%
340,100
-125,000
-27% -$6.95M
IMCR icon
79
Immunocore
IMCR
$1.7B
$17M 0.22%
+400,000
New +$17.8M
PCVX icon
80
Vaxcyte
PCVX
$7.71B
$16.8M 0.21%
850,000
– –
CTMX icon
81
CytomX Therapeutics
CTMX
$703M
$16.6M 0.21%
2,153,974
-423,069
-16% -$3.35M
NEPT
82
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$16.6M 0.21%
9,178
-6,690
-42% -$16.9M
ACRS icon
83
Aclaris Therapeutics
ACRS
$721M
$16.4M 0.21%
+650,000
New +$12.7M
CYPH
84
Cypherpunk Technologies Inc
CYPH
$64.9M
$16.1M 0.2%
847,650
– –
CMIIU
85
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
$16M 0.2%
+1,250,000
New +$15.7M
NBTX
86
Nanobiotix
NBTX
$1.9B
$15.9M 0.2%
1,059,800
-40,200
-4% -$691K
PNT
87
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$15.8M 0.2%
1,500,000
– –
ACCD
88
DELISTED
Accolade Inc
ACCD
$15.7M 0.2%
345,741
-280,850
-45% -$13.5M
HCAQ
89
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$14.9M 0.19%
+1,500,000
New +$15.4M
ADPT icon
90
Adaptive Biotechnologies
ADPT
$3.59B
$14.2M 0.18%
352,804
-552,050
-61% -$29.9M
VTRS icon
91
Viatris
VTRS
$20.9B
$14M 0.18%
1,004,419
– –
ACHL
92
DELISTED
Achilles Therapeutics
ACHL
$12.5M 0.16%
+755,375
New +$12.5M
CNCE
93
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$10.7M 0.14%
2,150,641
– –
BLSA
94
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$10.6M 0.13%
1,000,000
– –
CLOV icon
95
Clover Health Investments
CLOV
$2.24B
$10.3M 0.13%
+1,500,000
New +$16.9M
HRMY icon
96
Harmony Biosciences
HRMY
$2.07B
$10.3M 0.13%
311,673
-190,949
-38% -$6.7M
RACB
97
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$10.3M 0.13%
+1,000,000
New +$10.2M
TSHA icon
98
Taysha Gene Therapies
TSHA
$1.66B
$9.55M 0.12%
470,440
– –
XENE icon
99
Xenon Pharmaceuticals
XENE
$6.21B
$9.22M 0.12%
+515,042
New +$8.73M
PSTX
100
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$7.52M 0.1%
787,745
– –
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2021 Portfolio in Review

As of Q1 2021, Perceptive Advisors held 174 positions worth $7.91B, down 15% from $9.32B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Perceptive Advisors withdrew a net $1B in Q1 2021, closing 35 positions and reducing 37 holdings. Its most notable exit was Novavax, an estimated $116M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in Landos Biopharma, Inc. Common Stock worth $141M.

  • Perceptive Advisors's largest Q1 2021 buy was Landos Biopharma, Inc. Common Stock: 1,486,992 shares worth $141M.
  • Perceptive Advisors added most to BridgeBio Pharma in Q1 2021, an estimated $68.7M increase.
  • Perceptive Advisors's biggest Q1 2021 reduction was Neurocrine Biosciences, cutting an estimated $100M.
  • Perceptive Advisors fully exited Novavax in Q1 2021, selling an estimated $116M.
  • Perceptive Advisors's ten largest holdings make up 41% of its $7.91B portfolio in Q1 2021.
  • Perceptive Advisors opened 35 new positions and closed 35 in Q1 2021.
  • Perceptive Advisors's portfolio value fell 15% quarter-over-quarter to $7.91B.

Based on Perceptive Advisors's 13F filing for Q1 2021, filed 17 May 2021.